Recent developments in the therapeutic approach to risk factors related to cardiovascular disease have brought about significant advancements in the treatment of diabetes, obesity, and dyslipidemia. Experts in the field emphasize the importance of staying up to date with the latest pharmacological and therapeutic developments to reduce mortality rates associated with cardiovascular pathology, which remains the leading cause of death globally.
At the recent XX Vascular Risk Meeting of the Spanish Society of Internal Medicine (SEMI) held in Malaga, experts discussed the significant advancements in the treatment of obesity and diabetes in 2023. Dr. Alfredo Michan Doña highlighted the emergence of new drugs to treat obesity, such as retatrutide, a novel triple agonist that he described as fundamental. He also emphasized the latest developments in diabetes treatment, including new drugs like veneer nona and tirzepatida, which are expected to revolutionize the management of the disease.
Dr. Marta Casañas Martinez focused on advancements in dyslipidemia therapies, emphasizing the need for more effective treatment strategies and equitable access to medication. She highlighted promising drugs under study and the importance of combining therapies to achieve treatment goals more efficiently. However, she also noted disparities in the availability and use of these medications among internists in different regions, leading to unbalanced access for patients.
Overall, experts agree that staying informed about the latest research and innovations in cardiovascular disease treatment is essential for improving patient outcomes and reducing mortality rates. By incorporating new drugs and treatment strategies into clinical practice, healthcare professionals can make significant strides in combating cardiovascular disease and its associated risk factors.